Cinclus Pharma Holding AB (FRA:J8P) Operating Margin %: -905.04% (As of Mar. 2026)


FRA:J8P Cinclus Pharma Holding AB FRA:J8P
6 GF Score
Price €0.96
! 3 Warning Signs
View Full Analysis

What is Cinclus Pharma Holding AB Operating Margin %?

Cinclus Pharma Holding AB FRA:J8P -1.23% 6 Operating Margin % is -905.04% as of Mar. 2026. GuruFocus rates FRA:J8P with a GF Score™ of 6/100. The stock has 3 warning signs investors should review. Among 955 Drug Manufacturers companies, Cinclus Pharma Holding AB ranks worse than 94.76% on this metric.

Operating Margin % is calculated as Operating Income divided by its Revenue. Cinclus Pharma Holding AB's Operating Income for the three months ended in Mar. 2026 was €-8.44 Mil. Cinclus Pharma Holding AB's Revenue for the three months ended in Mar. 2026 was €0.93 Mil. Therefore, Cinclus Pharma Holding AB's Operating Margin % for the quarter that ended in Mar. 2026 was -905.04%.

The historical rank and industry rank for Cinclus Pharma Holding AB's Operating Margin % or its related term are showing as below:

FRA:J8P' s Operating Margin % Range Over the Past 10 Years
Min: -3688.45   Med: -2677.22   Max: -344.84
Current: -359.8


FRA:J8P's Operating Margin % is ranked worse than
94.76% of 955 companies
in the Drug Manufacturers industry
Industry Median: 7.45 vs FRA:J8P: -359.80

Cinclus Pharma Holding AB's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Cinclus Pharma Holding AB's Operating Income for the three months ended in Mar. 2026 was €-8.44 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Mar. 2026 was €-22.31 Mil.


Cinclus Pharma Holding AB  (FRA:J8P) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Cinclus Pharma Holding AB Operating Margin % Related Terms


Cinclus Pharma Holding AB Operating Margin % Historical Data

* Premium members only.

The historical data trend for Cinclus Pharma Holding AB's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cinclus Pharma Holding AB Operating Margin % Chart

Cinclus Pharma Holding AB Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Operating Margin %
0.00 -1,992.52 -3,359.29 -3,689.95 -344.84

Cinclus Pharma Holding AB Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -134.63 -452.71 -454.75 -905.04

FRA:J8P vs ZTS: Operating Margin % Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Cinclus Pharma Holding AB's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cinclus Pharma Holding AB Operating Margin % vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Cinclus Pharma Holding AB's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Cinclus Pharma Holding AB's Operating Margin % falls into.


FRA:J8P
6GF Score
Cinclus Pharma Holding AB FRA:J8P
Operating Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Cinclus Pharma Holding AB Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Cinclus Pharma Holding AB's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as

Operating Margin %=Operating Income (A: Dec. 2025 ) / Revenue (A: Dec. 2025 )
=-18.211 / 5.281
=-344.84 %

Cinclus Pharma Holding AB's Operating Margin % for the quarter that ended in Mar. 2026 is calculated as

Operating Margin %=Operating Income (Q: Mar. 2026 ) / Revenue (Q: Mar. 2026 )
=-8.435 / 0.932
=-905.04 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Operating Margin % →
What does a Operating Margin % of -905.04% mean?
Cinclus Pharma Holding AB (FRA:J8P) has a Operating Margin % of -905.04% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Cinclus Pharma Holding AB and its competitors. According to the industry distribution chart, Cinclus Pharma Holding AB ranks #905 out of 955 companies in the Drug Manufacturers industry, placing it in the top 94.8%.
Is Cinclus Pharma Holding AB's Operating Margin % too high?
Cinclus Pharma Holding AB's current Operating Margin % is -905.04%. Based on the distribution chart, Cinclus Pharma Holding AB ranks #905 out of 955 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Cinclus Pharma Holding AB has a GF Score™ of 6/100, reflecting its overall financial health beyond just this single metric.
How does Cinclus Pharma Holding AB's Operating Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Cinclus Pharma Holding AB ranks #905 out of 955 companies for Operating Margin %. This places Cinclus Pharma Holding AB in the lower half of its industry. The industry median Operating Margin % is 7.45. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Drug Manufacturers company?
The median Operating Margin % among Drug Manufacturers companies is 7.45, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Cinclus Pharma Holding AB and its competitors. For the Drug Manufacturers industry, the median Operating Margin % is 7.45 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Cinclus Pharma Holding AB's current Operating Margin % is -905.04%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Cinclus Pharma Holding AB stock overvalued right now?
Cinclus Pharma Holding AB (FRA:J8P) has a current Operating Margin % of -905.04%. The current Operating Margin % is -905.04%. Cinclus Pharma Holding AB's overall GF Score™ is 6/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Cinclus Pharma Holding AB (FRA:J8P), the current Operating Margin % is -905.04% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Cinclus Pharma Holding AB Business Description

Other Exchanges CINPHA:Sweden
Address Kungsbron 1, Stockholm, SWE, SE-111 22
Cinclus Pharma Holding AB is a Swedish clinical-stage pharmaceutical company focused on developing small-molecule treatments for gastric acid-related diseases. Its candidate, linaprazan glurate, is being developed for the treatment of severe gastroesophageal reflux disease, including erosive forms. The company is also developing a dual therapy treatment with an antibiotic targeting Helicobacter pylori, a bacterium found in the gastric and duodenal mucosa. Its primary target population consists of patients with severe erosive gastroesophageal reflux disease, where current treatment options are limited. It operates in Switzerland, Sweden, and the Czech Republic, with the majority of revenue from the Czech Republic.
6GF Score

Get the complete analysis for FRA:J8P

Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.96
Price